Affitech and Omeros in antibody development deal
This article was originally published in Scrip
Executive Summary
Norway's Affitech and Omeros have signed an agreement to discover and develop fully human antibodies against inflammatory diseases for Omeros's MASP-2 (mannan-binding lectin-associated serine protease-2) programme. The agreement will advance Omeros's programme, and allow Affitech to expand a portfolio that is mainly focused on oncology. The US company will pay a technology-access fee, milestone payments and royalties on net sales. No further details were released owing to pre-IPO restrictions; Omeros filed an IPO with the US SEC to float on Nasdaq earlier this year (Scrip Online, January 14th, 2008). It holds the worldwide rights related to MASP-2 from the UK's University of Leicester and its collaborator, the Medical Research Council at Oxford University. They cover antibodies targeting MASP-2 and the therapeutic applications for those antibodies, MASP-2 is required for the function of a principal complement activation pathway, known as the lectin pathway. Its abnormal function is associated with a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis and cardiovascular and renal ischaemia-reperfusion therapy. Antibody therapies represent one of the fastest-growing sectors within the pharmaceutical industry, with sales forecast to reach $30 billion in 2008, according to Business Insight.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.